58 results on '"Granger, C B"'
Search Results
2. Multiplex screening for biomarkers associated with subsequent heart failure hospitalisation in patients with atrial fibrillation: insights from the ARISTOTLE trial
3. Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin
4. Blood stream infection in patients with implantable-cardioverter defibrillator admitted to non-cardiology units: incidence, diagnostic work-up and outcome
5. Causes of death in patients with atrial fibrillation and a recent acute coronary syndrome or percutaneous coronary intervention: insights from the AUGUSTUS trial
6. Oral Presentation No. 53 Dose-related preprocedural patency of the infarct-related artery after zalunfiban (RUC-4) administration upon arrival at the catheterization laboratory in ST-elevation myocardial infarction: insights from the phase IIa study
7. Incidence and risk factors for major bleeding events in atrial fibrillation patients on direct oral anticoagulant therapy: data from the National Patient-Centered Clinical Research Network
8. P4774Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study
9. P4747Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation
10. P5471Baseline characteristics, healthcare resource use and clinical outcomes of stable post-myocardial infarction patients with diabetes: insights from the global prospective TIGRIS study
11. 286Predictors of atrial fibrillation in patients with embolic stroke of undetermined source: an analysis of the RE-SPECT ESUS trial
12. P1932Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study
13. P4752Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
14. P3640Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy
15. P4396Patients explanations of self-care in chronic heart failure: a grounded theory analysis of qualitative data from PANACEA-HF Phase 1
16. P4453Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial
17. P5793Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE
18. P3840Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation
19. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease
20. Roger et al. Respond to "Future of Population Studies"
21. Strategic Transformation of Population Studies: Recommendations of the Working Group on Epidemiology and Population Sciences From the National Heart, Lung, and Blood Advisory Council and Board of External Experts
22. Should patients on vitamin K antagonists be treated differently?
23. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
24. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program
25. The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions
26. Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?
27. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
28. Large streamlined trials in cardiovascular disease
29. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
30. Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction
31. Physical activity in patients with stable coronary heart disease: an international perspective
32. Alcohol Withdrawal Prevention: A Randomized Evaluation of Lorazepam and Ethanol--A Pilot Study
33. Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial
34. Biomarkers in atrial fibrillation: a clinical review
35. Reasons for Noncompletion of Advance Directives in a Cardiac Intensive Care Unit
36. Who should have a routine early invasive approach after fibrinolytic therapy?
37. Differences in Level of Care at the End of Life According to Race
38. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial
39. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
40. No difference in peak troponin level in immediate versus delayed (next working day) intervention for acute coronary syndrome without ST-segment elevation
41. Clinical trials and registries in cardiovascular disease: competitive or complementary?
42. Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI
43. The authors' reply
44. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
45. Review: an early invasive strategy has similar benefits in men and women with NSTEMI or unstable angina
46. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
47. Polymorphisms of the Tumor Suppressor Gene LSAMP are Associated with Left Main Coronary Artery Disease
48. Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb
49. Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure
50. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.